Status:
COMPLETED
Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Lymphoma
Eligibility:
All Genders
Phase:
PHASE1
Brief Summary
The goal of this clinical research study is to see how well the drugs 2CdA, cyclophosphamide, and rituximab (rituxan) shrink a lymphoma called Waldenstrom's macroglobulinemia. After these drugs are gi...
Detailed Description
Before the study starts, patients will have a complete exam. Blood and urine tests will be done. A bone marrow test, a chest x-ray and a CT scan of the abdomen will be done if not studied recently. B...
Eligibility Criteria
Inclusion
- Newly diagnosed patients with symptomatic macroglobulinemic lymphoma are eligible. Macroglobulinemic lymphoma includes patients with either biopsy proven small lymphocytic lymphoma or chronic lymphocytic leukemia and monoclonal IgM. Also included are symptomatic patients with clonal proliferation producing a pathologic monoclonal IgM that causes cryoglobulinemia, peripheral neuropathy or cold agglutinin hemolytic anemia.
- Patients must have adequate liver function (bilirubin \<2.5 mg%) and renal function (creatinine \<2.0 mg%).
Exclusion
- None.
Key Trial Info
Start Date :
July 9 1999
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2022
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00667329
Start Date
July 9 1999
End Date
February 10 2022
Last Update
March 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030